ARMO BioSciences, Inc.

Even with less venture capital raised during the first quarter of 2022 than in Q1 of 2021, VC financing has become the most common type of financing for biopharmaceutical firms raising cash in 2022, a

Eli Lilly & Co. is going through a reorganization of its cancer research and development operations, and early changes since the pharma turned this responsibility over to the executive team from Lox

Eli Lilly & Co. ’s turnaround in oncology has been a long time coming. It’s been a historic focus for the Indianapolis-based biopharma, and the company has made some sizeable additions in recent years

Eli Lilly & Co. paired its third quarter earnings call with news of a big leadership change. Longtime diabetes executive Enrique Conterno will be retiring at year’s end, to be succeeded by a fellow L